Nociceptin/orphanin FQ receptor ligands

被引:79
作者
Calo, G
Bigoni, R
Rizzi, A
Guerrini, R
Salvadori, S
Regoli, D
机构
[1] Univ Ferrara, Pharmacol Sect, Dept Expt & Clin Med, I-44100 Ferrara, Italy
[2] Univ Ferrara, Dept Pharmaceut Sci, I-44100 Ferrara, Italy
[3] Univ Ferrara, Ctr Biotechnol, I-44100 Ferrara, Italy
关键词
nociceptin; orphanin FQ; nociceptin orphanin FQ receptor; receptor ligands; agonists and antagonists; pharmacological assays;
D O I
10.1016/S0196-9781(00)00230-8
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Nociceptin (NC), alias Orphanin FQ (OFQ) is a heptadecapeptide structurally related to opioid peptides, especially Dynorphin A, which, however, does not interact with classic opioid receptors. NC selectively activates its own receptor (OP4), which has been shown to be insensitive to the naturally occurring opioid peptides as well as to a large number of non-peptide opioid receptor ligands, including naloxone. Thus, the NC/OP4 system represents a new peptide-based signaling pathway, which is pharmacologically distinct from the opioid systems. The pharmacological tools available for investigating NC actions are at present rather limited and include: I)peptide ligands obtained from structure activity studies performed using NC(1-13)NH2 as a template or discovered by screening peptide combinatorial libraries; 2) nonpeptide ligands that are either molecules already known to interact with classic opioid receptors or novel molecules designed and synthesized as selective ligands of the OP4 receptor. In the present paper the functional data obtained from both in vitro and in vivo studies with each relevant OP4 receptor ligand will be analyzed and discussed comparing the advantages and disadvantages of each molecule. We hope that the present work will aid investigators, working in the NC/OP4 field, in the choice of the pharmacological tools suitable fur their experiments. (C) 2000 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:935 / 947
页数:13
相关论文
共 100 条
[31]  
CORBETT AD, 1998, N-S ARCH PHARMACOL, V358, P47
[32]  
Dhawan BN, 1996, PHARMACOL REV, V48, P567
[33]   Orphanin FQ: Receptor binding and analog structure activity relationships in rat brain [J].
Dooley, CT ;
Houghten, RA .
LIFE SCIENCES, 1996, 59 (01) :PL23-PL29
[34]  
Dooley CT, 1997, J PHARMACOL EXP THER, V283, P735
[35]   Pre- and postsynaptic actions of opioid and orphan opioid agonists in the rat arcuate nucleus and ventromedial hypothalamus in vitro [J].
Emmerson, PJ ;
Miller, RJ .
JOURNAL OF PHYSIOLOGY-LONDON, 1999, 517 (02) :431-445
[36]  
GRESSENS P, 1999, REGUL PEPTIDES, V80, P123
[37]   [Phe1ψ(CH2-NH)Gly2]nociceptin-(1-13)-NH2 acts as an agonist of the orphanin FQ nociceptin receptor in vivo [J].
Grisel, JE ;
Farrier, DE ;
Wilson, SG ;
Mogil, JS .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 357 (01) :R1-R3
[38]   Address and message sequences for the nociceptin receptor: A structure-activity study of nociceptin-(1-13)-peptide amide [J].
Guerrini, R ;
Calo, G ;
Rizzi, A ;
Bianchi, C ;
Lazarus, LH ;
Salvadori, S ;
Temussi, PA ;
Regoli, D .
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (12) :1789-1793
[39]   A new selective antagonist of the nociceptin receptor [J].
Guerrini, R ;
Calo, G ;
Rizzi, A ;
Bigoni, R ;
Bianchi, C ;
Salvadori, S ;
Regoli, D .
BRITISH JOURNAL OF PHARMACOLOGY, 1998, 123 (02) :163-165
[40]  
GUERRINI R, 1999, REGUL PEPTIDES, V80, P124